Eflornithine

Brand names: Iwilfin · Active ingredient: Eflornithine Hydrochloride

In short: IWILFIN (eflornithine) is indicated to reduce the risk of relapse in adult and pediatric patients with high-risk neuroblastoma (HRNB) who have demonstrated at least a partial response to prior multiagent, multimodality therapy including anti-GD2 immunotherapy.

Forms & strengthsTablets: 192 mg eflornithine, white to off-white, round, imprinted with "EFL" on one side and "192" on the other side.
LabelUswm, Llc
Label updatedMar 30, 2026

What is Eflornithine used for?

IWILFIN (eflornithine) is indicated to reduce the risk of relapse in adult and pediatric patients with high-risk neuroblastoma (HRNB) who have demonstrated at least a partial response to prior multiagent, multimodality therapy including anti-GD2 immunotherapy.

Eflornithine dosage

Prior to initiating IWILFIN, perform complete blood count, liver function tests, and baseline audiogram .

The recommended IWILFIN dosage, based on body surface area (BSA), is provided in Table 1.

Administer IWILFIN orally twice daily for two years or until recurrence of disease or unacceptable toxicity.

Recalculate the BSA dosage every 3 months during treatment with IWILFIN.

Body Surface Area (m2) | Dosage

>1.5 | 768 mg (four tablets) orally twice a day

0.75 to 1.5 | 576 mg (three tablets) orally twice a day

0.5 to < 0.75 | 384 mg (two tablets) orally twice a day

0.25 to < 0.5 | 192 mg (one tablet) orally twice a day

For the treatment of patients with severe renal impairment (eGFR <30 mL/min), reduce the recommended dose of IWILFIN by 50% as described in Table 2 .

Body Surface Area (m2) | Recommended Dosage for Patients with Severe Renal Impairment (eGFR <30 mL/min)

>1.5 | 384 mg (two tablets) orally twice a day

0.75 to 1.5 | 384 mg (two tablets) in the morning and 192 mg (one tablet) in the evening

0.5 to < 0.75 | 192 mg (one tablet) orally twice a day

0.25 to < 0.5 | 192 mg (one tablet) once a day

The recommended dose reductions for adverse reactions are provided in Table 3.

Current Dose | Reduced Dose

768 mg (four tablets) orally twice a day | 576 mg (three tablets) orally twice a day

576 mg (three tablets) orally twice a day | 384 mg (two tablets) orally twice a day

384 mg (two tablets) orally twice a day | 192 mg (one tablet) orally twice a day

192 mg (one tablet) orally twice a day | 192 mg (one tablet) orally once daily

If subsequent adverse reactions occur, continue dose reduction until reaching the minimum dose of one 192 mg tablet once per day. Permanently discontinue IWILFIN if the patient is unable to tolerate the minimum dose of 192 mg once daily.

The recommended dosage modifications of IWILFIN for the management of adverse reactions are provided in Table 4.

Adverse Reaction | SeveritySeverity as defined by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03 | Dosage Modification

Myelosuppression

Neutrophil count decreased | <500/mm3 | Withhold IWILFIN until recovery to ≥500/mm3.

If recovered within 7 days, resume IWILFIN at the same dose.

If recovered after 7 days, resume IWILFIN at the next reduced dose level.

Platelet count decreased | <25,000/mm3 | Withhold IWILFIN until recovery to ≥25,000/mm3.

If recovered within 7 days, resume IWILFIN at the same dose.

If recovered between 7 and 14 days, resume IWILFIN at the next reduced dose level.

If not recovered within 14 days, permanently discontinue IWILFIN.

Anemia | <8g/dL | Withhold IWILFIN until recovery to ≥8g/dL.

Resume IWILFIN at the same dose.

If anemia recurs (<8g/dL)

Withhold IWILFIN until recovery to ≥8g/dL. …

How to take Eflornithine — instructions & advice from the label

Advise the patient to read the FDA-approved patient labeling (Patient Information).

Myelosuppression

Inform patients and caregivers of the risk of bone marrow suppression and to promptly report any signs or symptoms of thrombocytopenia, anemia, or infection .

Hepatotoxicity

Inform patients and caregivers of the risk of hepatotoxicity and to promptly report any signs or symptoms of hepatotoxicity .

Hearing Loss

Inform patients and caregivers of the risk of hearing loss, and to promptly report any signs or symptoms of new or worsening hearing loss .

Embryofetal Toxicity

Inform patients and caregivers that IWILFIN can be harmful to a developing fetus and cause loss of pregnancy . Advise females of reproductive potential to use effective contraception during treatment with IWILFIN and for 1 week after the last dose. Advise males with female partners of reproductive potential to use effective contraception during treatment with IWILFIN and for 1 week after the last dose .

Lactation

Advise women not to breastfeed during treatment with IWILFIN and for 1 week after the last dose .

Warnings & precautions

Do not take this medicine if: None.

IWILFIN can cause myelosuppression. In the pooled safety population , Grade 3 or 4 neutropenia occurred in 4.2% of patients. Febrile neutropenia occurred in 0.6% of patients. Bone marrow failure occurred in 1 patient. Grade 3 or 4 thrombocytopenia occurred in 1.4% of patients. Grade 3 anemia occurred in 3.3% of patients.

Monitor blood counts including neutrophil count, platelet count, and hemoglobin level prior to administration of IWILFIN and periodically during treatment. Withhold, reduce the dose, or permanently discontinue IWILFIN based on severity .

IWILFIN can cause hepatotoxicity. In the pooled safety population , Grade 3 or 4 events of increased alanine aminotransferase (ALT) occurred in 11% of patients. Grade 3 or 4 events of increased aspartate aminotransferase (AST) occurred in 6% of patients. Grade 3 or 4 events of increased bilirubin occurred in 0.3% of patients. Increased ALT/AST leading to dose interruption or reduction occurred in 2.5% of patients. IWILFIN was discontinued due to increased ALT/AST in 0.6% of patients.

Perform liver function tests (ALT, AST, and total bilirubin) prior to the start of IWILFIN, every month for the first six months of treatment, then once every 3 months or as clinically indicated, with more frequent testing in patients who develop transaminase or bilirubin elevations. Withhold and reduce the dose or permanently discontinue IWILFIN based on severity .

IWILFIN can cause hearing loss. In the pooled safety population , 81% of patients had an abnormal audiogram at baseline. New or worsening hearing loss occurred in 13% of patients who received IWILFIN; hearing loss worsened from baseline to Grade 3 or 4 in 12% of patients. Tinnitus occurred in 1 patient. Hearing loss leading to dose interruption or reduction occurred in 4% of patients. …

Eflornithine side effects

The following clinically significant adverse reactions are described elsewhere in the labeling:

Myelosuppression

Hepatotoxicity

Hearing Loss

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect rates observed in clinical practice.

The pooled safety population described in the WARNINGS AND PRECAUTIONS reflect exposure to IWILFIN as a single agent, taken orally at doses ranging from 192 - 768 mg twice daily, based on body surface area (BSA), until disease progression, unacceptable toxicity, or for a maximum of 2 years in patients who demonstrated at least a partial response to prior multiagent, multimodality therapy for newly diagnosed or relapsed/refractory high-risk neuroblastoma in Study 3b (n=101; NCT02395666) and Study 14 (n=259; NCT02679144). Among 360 patients who received IWILFIN, 84% were exposed for 6 months or longer and 73% were exposed for greater than one year. In this pooled safety population, the most common (≥5%) adverse reactions were hearing loss (11%), otitis media (10%), pyrexia (7%), pneumonia (5%), and diarrhea (5%). The most common (≥2%) Grade 3 or 4 laboratory abnormalities were increased ALT (11%), increased AST (6%), decreased neutrophils (4.2%), and decreased hemoglobin (3.3%).

Study 3b

The safety of IWILFIN was evaluated in Study 3b . …

About this medicine

IWILFIN is an ornithine decarboxylase inhibitor. The chemical name of eflornithine hydrochloride is 2,5-diamino-2-(difluoromethyl) pentanoic acid hydrochloride hydrate with a molecular formula of C6H12F2N2O2∙HCl∙H2O. Its molecular weight is 236.65g/mol for the salt and hydrate form and 182.17 g/mol for the anhydrous free base form. Eflornithine hydrochloride is a white to off-white powder, freely soluble in water and sparingly soluble in ethanol. The chemical structure of eflornithine hydrochloride is:

IWILFIN is available as a round, white to off-white tablet for oral administration. Each tablet contains 192 mg eflornithine, equivalent to 250 mg of eflornithine hydrochloride, and the following inactive ingredients: 220 mg silicified microcrystalline cellulose, 25 mg partially pregelatinized maize starch, 2.5 mg colloidal silicon dioxide, and 2.5 mg vegetable source magnesium stearate. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 6716d8cc-66e6-4cee-935c-ccb85ed984f5. Read the full official label on DailyMed.